Psychopharmacologic treatment of children and adolescents with anxiety disorders.

Journal Article (Journal Article;Review)

Over the last decade, psychopharmacologic treatments for pediatric anxiety disorders have been developed and increasingly subjected to randomized, controlled trials. The authors summarize the data concerning the use of tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), atypical anxiolytics, and benzodiazepines. The extant data suggest that SSRIs--both as monotherapy and when combined with psychotherapy--are effective in the treatment of pediatric anxiety disorders. In addition, some TCAs and SNRIs are effective. However, randomized controlled trials do not suggest efficacy for benzodiazepines or the atypical anxiolytic, buspirone, for children and adolescents with anxiety disorders.

Full Text

Duke Authors

Cited Authors

  • Strawn, JR; Sakolsky, DJ; Rynn, MA

Published Date

  • July 2012

Published In

Volume / Issue

  • 21 / 3

Start / End Page

  • 527 - 539

PubMed ID

  • 22800992

Electronic International Standard Serial Number (EISSN)

  • 1558-0490

Digital Object Identifier (DOI)

  • 10.1016/j.chc.2012.05.003


  • eng

Conference Location

  • United States